Comparative Pharmacology
Head-to-head clinical analysis: CRIXIVAN versus EMZAHH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRIXIVAN versus EMZAHH.
CRIXIVAN vs EMZAHH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indinavir is a specific, potent, reversible inhibitor of HIV-1 protease. It binds to the active site of the viral protease, preventing the cleavage of viral polyprotein precursors into functional proteins, resulting in the formation of immature, non-infectious virions.
EMZAHH is a monoclonal antibody that targets and binds to the human epidermal growth factor receptor 2 (HER2), inhibiting downstream signaling pathways involved in cell proliferation and survival.
800 mg orally every 8 hours on an empty stomach (1 hour before or 2 hours after meals) or with a light meal.
10 mg orally twice daily without regard to meals.
None Documented
None Documented
Terminal elimination half-life is 1.8 to 2.5 hours in healthy adults; requires dosing every 8 hours.
Terminal elimination half-life 12 hours, requiring twice-daily dosing for steady state
Primarily fecal (78-82%) with approximately 20% renal excretion of unchanged drug.
Renal 40% unchanged, fecal 50% as metabolites, biliary 10%
Category C
Category C
Antiretroviral
Antiretroviral, Integrase Inhibitor + NRTIs